Published in Brain Pathol on April 01, 2007
Age-dependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci (2008) 3.24
Disease-specific molecular events in cortical multiple sclerosis lesions. Brain (2013) 2.48
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Multiple sclerosis-a quiet revolution. Nat Rev Neurol (2015) 1.47
Cortical lesions in multiple sclerosis. Nat Rev Neurol (2010) 1.47
The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol (2009) 1.29
Meningeal and cortical grey matter pathology in multiple sclerosis. BMC Neurol (2012) 1.27
A combined post-mortem magnetic resonance imaging and quantitative histological study of multiple sclerosis pathology. Brain (2012) 1.22
Tight junctions potentiate the insulative properties of small CNS myelinated axons. J Cell Biol (2008) 1.10
Remyelination therapy for multiple sclerosis. Neurotherapeutics (2013) 1.08
NG2 cells (polydendrocytes): listeners to the neural network with diverse properties. Glia (2014) 1.04
Transplantation reveals regional differences in oligodendrocyte differentiation in the adult brain. Nat Neurosci (2013) 1.02
Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol (2012) 1.00
Focal cortical lesion detection in multiple sclerosis: 3 Tesla DIR versus 7 Tesla FLASH-T2. J Magn Reson Imaging (2011) 0.97
From fish to man: understanding endogenous remyelination in central nervous system demyelinating diseases. Brain (2008) 0.96
NG2 cells in white matter but not gray matter proliferate in response to PDGF. J Neurosci (2013) 0.95
An N-terminally truncated envelope protein encoded by a human endogenous retrovirus W locus on chromosome Xq22.3. Retrovirology (2010) 0.93
Neural stem cell niches in health and diseases. Curr Pharm Des (2012) 0.91
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis. Prog Neurobiol (2008) 0.91
Quantitative magnetic resonance imaging of cortical multiple sclerosis pathology. Mult Scler Int (2012) 0.90
Detecting microstructural properties of white matter based on compartmentalization of magnetic susceptibility. Neuroimage (2012) 0.90
Myelin repair strategies: a cellular view. Curr Opin Neurol (2008) 0.89
Spatial and temporal profiles of growth factor expression during CNS demyelination reveal the dynamics of repair priming. PLoS One (2011) 0.89
NG2-glia and their functions in the central nervous system. Glia (2015) 0.87
Neuroprotection and neuroregeneration in multiple sclerosis. J Neurol (2008) 0.84
Whole-Brain In-vivo Measurements of the Axonal G-Ratio in a Group of 37 Healthy Volunteers. Front Neurosci (2015) 0.84
Axonal damage in the making: neurofilament phosphorylation, proton mobility and magnetisation transfer in multiple sclerosis normal appearing white matter. Exp Neurol (2011) 0.83
Interplay between mechanisms of damage and repair in multiple sclerosis. J Neurol (2008) 0.83
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation. Magn Reson Imaging (2012) 0.82
Oligodendroglia in cortical multiple sclerosis lesions decrease with disease progression, but regenerate after repeated experimental demyelination. Acta Neuropathol (2014) 0.81
Grey matter lesions in MS: from histology to clinical implications. Prion (2012) 0.81
Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter. J Magn Reson Imaging (2010) 0.80
Hypoperfusion and T1-hypointense lesions in white matter in multiple sclerosis. Mult Scler (2013) 0.80
Gray Matter Pathology in MS: Neuroimaging and Clinical Correlations. Mult Scler Int (2013) 0.80
A revised model for estimating g-ratio from MRI. Neuroimage (2015) 0.79
Novel pathologic findings in patients with Pelizaeus-Merzbacher disease. Neurosci Lett (2016) 0.78
Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report. Neurol Sci (2011) 0.78
Advanced MRI and staging of multiple sclerosis lesions. Nat Rev Neurol (2016) 0.77
Heterogeneity in oligodendroglia: Is it relevant to mouse models and human disease? J Neurosci Res (2016) 0.76
Gene expression changes underlying cortical pathology: clues to understanding neurological disability in multiple sclerosis. Mult Scler (2013) 0.76
Characterizing axonal myelination within the healthy population: a tract-by-tract mapping of effects of age and gender on the fiber g-ratio. Neurobiol Aging (2016) 0.76
Enhanced expression of matrix metalloproteinase-12 contributes to Npc1 deficiency-induced axonal degeneration. Exp Neurol (2015) 0.76
Promoting return of function in multiple sclerosis: An integrated approach. Mult Scler Relat Disord (2013) 0.76
Neuronopathy in the motor neocortex in a chronic model of multiple sclerosis. J Neuropathol Exp Neurol (2014) 0.75
Spring cleaning: time to rethink imaging research lines in MS? J Neurol (2016) 0.75
7T MRI Visualization of Cortical Lesions in Adolescents and Young Adults with Pediatric-Onset Multiple Sclerosis. J Neuroimaging (2017) 0.75
Normal appearing white matter permeability: a marker of inflammation and information processing speed deficit among relapsing remitting multiple sclerosis patients. Neuroradiology (2017) 0.75
[Computational neuroanatomy and microstructure imaging using magnetic resonance imaging]. Nervenarzt (2017) 0.75
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Microglia in the adult brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. Nat Neurosci (2007) 6.23
The development of inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol (2007) 5.83
Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain (2005) 5.29
Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol (2009) 4.88
The immunopathology of multiple sclerosis: an overview. Brain Pathol (2007) 4.23
Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med (2011) 4.02
Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity (2008) 3.67
Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain (2011) 3.38
Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol (2009) 3.35
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain (2009) 3.04
A reversible form of axon damage in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med (2011) 3.00
Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet (2005) 2.68
CCR2+Ly-6Chi monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain (2009) 2.59
Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis. Brain (2007) 2.46
Remyelination is extensive in a subset of multiple sclerosis patients. Brain (2006) 2.43
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain (2002) 2.27
Microglial phenotype: is the commitment reversible? Trends Neurosci (2006) 2.18
Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis. J Clin Invest (2006) 2.17
Tissue preconditioning may explain concentric lesions in Baló's type of multiple sclerosis. Brain (2005) 2.07
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch Neurol (2007) 1.86
Staging of neurofibrillary pathology in Alzheimer's disease: a study of the BrainNet Europe Consortium. Brain Pathol (2008) 1.85
Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis. Proc Natl Acad Sci U S A (2006) 1.79
Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci (2002) 1.78
Mechanisms of acute axonal degeneration in the optic nerve in vivo. Proc Natl Acad Sci U S A (2010) 1.70
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology (2012) 1.67
Circulating monocytes engraft in the brain, differentiate into microglia and contribute to the pathology following meningitis in mice. Brain (2006) 1.63
Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain (2007) 1.63
Thermal hypoaesthesia differentiates secondary restless legs syndrome associated with small fibre neuropathy from primary restless legs syndrome. Brain (2010) 1.62
Acute effects of intracranial hypertension and ARDS on pulmonary and neuronal damage: a randomized experimental study in pigs. Intensive Care Med (2011) 1.57
Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol (2003) 1.55
Effects of interferon-beta-1a on neuronal survival under autoimmune inflammatory conditions. Exp Neurol (2006) 1.55
Reduced astrocytic NF-κB activation by laquinimod protects from cuprizone-induced demyelination. Acta Neuropathol (2012) 1.53
Microglia inflict delayed brain injury after subarachnoid hemorrhage. Acta Neuropathol (2015) 1.51
Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol (2007) 1.49
Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest (2008) 1.44
Iron and neurodegeneration in the multiple sclerosis brain. Ann Neurol (2013) 1.43
Microglial expression of the B7 family member B7 homolog 1 confers strong immune inhibition: implications for immune responses and autoimmunity in the CNS. J Neurosci (2005) 1.43
Remyelination in multiple sclerosis. J Neurol Sci (2003) 1.43
IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous activation of NF-kappaB in the central nervous system. Brain (2011) 1.37
A new focal EAE model of cortical demyelination: multiple sclerosis-like lesions with rapid resolution of inflammation and extensive remyelination. Brain (2006) 1.35
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 1.33
Immunological and clinical consequences of treating a patient with natalizumab. Mult Scler (2011) 1.33
Targeting experimental autoimmune encephalomyelitis lesions to a predetermined axonal tract system allows for refined behavioral testing in an animal model of multiple sclerosis. Am J Pathol (2004) 1.31
Cortical pathology in multiple sclerosis. Curr Opin Neurol (2008) 1.31
Related B cell clones that populate the CSF and CNS of patients with multiple sclerosis produce CSF immunoglobulin. J Neuroimmunol (2011) 1.27
Diminished Th17 (not Th1) responses underlie multiple sclerosis disease abrogation after hematopoietic stem cell transplantation. Ann Neurol (2013) 1.27
T cell-dependence of Lassa fever pathogenesis. PLoS Pathog (2010) 1.25
Enhancing remyelination in disease--can we wrap it up? Brain (2011) 1.25
Primary hypophysitis: clinical-pathological correlations. Eur J Endocrinol (2006) 1.25
Remodeling of axonal connections contributes to recovery in an animal model of multiple sclerosis. J Exp Med (2004) 1.25
Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta (2010) 1.20
Multicontrast MRI of remyelination in the central nervous system. NMR Biomed (2005) 1.19
A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain (2003) 1.18
Pathogenesis of multiple sclerosis. Curr Opin Neurol (2005) 1.16
Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol (2013) 1.16
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol (2010) 1.15
Cell type-specific Nrf2 expression in multiple sclerosis lesions. Acta Neuropathol (2015) 1.15
Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol (2003) 1.15
Inter-laboratory comparison of neuropathological assessments of beta-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathol (2008) 1.13
Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia (2010) 1.13
Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging (2008) 1.12
Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol (2011) 1.12
TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis. Nat Med (2012) 1.11
Negative impact of statins on oligodendrocytes and myelin formation in vitro and in vivo. J Neurosci (2008) 1.10
Suppression of Rac activity induces apoptosis of human glioma cells but not normal human astrocytes. Cancer Res (2002) 1.10
Microglial nodules in early multiple sclerosis white matter are associated with degenerating axons. Acta Neuropathol (2013) 1.08
Naive CD8 T-cells initiate spontaneous autoimmunity to a sequestered model antigen of the central nervous system. Brain (2008) 1.08
Toll-like receptor activation reveals developmental reorganization and unmasks responder subsets of microglia. Glia (2012) 1.08
Specific central nervous system recruitment of HLA-G(+) regulatory T cells in multiple sclerosis. Ann Neurol (2009) 1.08
The spectrum of multiple sclerosis: new lessons from pathology. Curr Opin Neurol (2005) 1.07
Lipopolysaccharide injection induces relapses of experimental autoimmune encephalomyelitis in nontransgenic mice via bystander activation of autoreactive CD4+ cells. J Immunol (2005) 1.06
Assessment of lesion pathology in a new animal model of MS by multiparametric MRI and DTI. Neuroimage (2011) 1.06
Combined therapy with methylprednisolone and erythropoietin in a model of multiple sclerosis. Brain (2004) 1.04
Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol (2003) 1.04
Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis. Brain Pathol (2008) 1.02
Wallerian degeneration: a major component of early axonal pathology in multiple sclerosis. Brain Pathol (2010) 1.02
Differential upregulation of heme oxygenase-1 (HSP32) in glial cells after oxidative stress and in demyelinating disorders. J Mol Neurosci (2007) 1.02